Evidence map›Paper›PMID 31864668›Full record

ArticleOphthalmology2020

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.

Richard F Spaide, Glenn J Jaffe, David Sarraf, K Bailey Freund, Srinivas R Sadda, Giovanni Staurenghi, Nadia K Waheed, Usha Chakravarthy, Philip J Rosenfeld, Frank G Holz and 25 more

Erratum issuedOpen access · hybridAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 478 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
478citing papers in PubMed, 4 pooled it
45.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

478 citing papers in PubMed, 4 syntheses or guidelines pooled it, 746 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Choroidal vascularity across aging and the spectrum of age-related macular degeneration: an AI-based OCT study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  17. Eighteen-month real-world outcomes of intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration: a UK single-centre experience.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  18. Article
  19. Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  20. Article

418 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 10 countries.

Richard F SpaideVitreous Retina Macula Consultants of New York, New York, New York. Electronic address: rickspaide@gmail.com.
Glenn J JaffeDepartment of Ophthalmology, Duke University, Durham, North Carolina.
David SarrafDoheny Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California.
K Bailey FreundVitreous Retina Macula Consultants of New York, New York, New York.
Srinivas R SaddaDoheny Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California.
Giovanni StaurenghiSan Raffaele Scientific Institute, Milan, Italy.
Nadia K WaheedNew England Eye Center, Tufts University, Boston, Massachusetts.
Usha ChakravarthyCenter for Public Health, The Queen's University of Belfast, Belfast, United Kingdom.
Philip J RosenfeldBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.
Frank G HolzDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Eric H SouiedDepartment of Ophthalmology, Université Paris-Est Créteil, Paris, France.
Salomon Y CohenOphthalmic Center for Imaging and Laser, Paris, France.
Giuseppe QuerquesIRCCS San Raffaele Hospital, University Vita-Salute San Raffele, Milan, Italy.
Kyoko Ohno-MatsuiDepartment of Ophthalmology, Tokyo Medical and Dental University, Tokyo, Japan.
David BoyerRetina-Vitreous Associates Medical Group, Los Angeles, California.
Alain GaudricDepartment of Ophthalmology, Hôpital Lariboisière, AP-HP, Université de Paris, Paris, France.
Barbara BlodiDepartment of Ophthalmology and Visual Sciences, Fundus Photograph Reading Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Caroline R BaumalNew England Eye Center, Tufts University, Boston, Massachusetts.
Xiaoxin LiDepartment of Ophthalmology, People's Eye Center of People's Hospital of Beijing University, Beijing, China.
Gabriel J CoscasDepartment of Ophthalmology, University of Paris XII, Paris, France.
Alexander BruckerDepartment of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
Lawrence SingermanDepartment of Ophthalmology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Phil LuthertInstitute of Ophthalmology, University College London, London, United Kingdom.
Steffen Schmitz-ValckenbergDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Ursula Schmidt-ErfurthDepartment of Ophthalmology, University Eye Hospital, Vienna, Austria.
Hans E GrossniklausEmory Eye Center, Atlanta, Georgia.
David J WilsonOregon Health Science University, Portland, Oregon.
Robyn GuymerCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Department of Surgery (Ophthalmology), University of Melbourne, Melbourne, Australia.
Lawrence A YannuzziVitreous Retina Macula Consultants of New York, New York, New York.
Emily Y ChewNational Eye Institute, National Institutes of Health, Bethesda, Maryland.
Karl CsakyTexas Retina Associates, Dallas, Texas.
Jordi M MonésInstitut de la Màcula and Barcelona Macula Foundation, Barcelona, Spain.
Daniel PauleikhoffDepartment of Ophthalmology, St. Franziskus Hospital, Münster, Germany.
Ramin TadayoniDepartment of Ophthalmology, Hôpital Lariboisière, AP-HP, Université de Paris, Paris, France.
James FujimotoDepartment of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Vitreous Retina Macula Consultants of New York · USTufts University · USUniversité Paris Cité · FRUniversity of Bonn · DEUniversity of California, Los Angeles · USBarcelona Macula Foundation · ESCentre Ophtalmologique d'Imagerie et de Laser · FRDuke University · USEmory Eye Center · USMassachusetts Institute of Technology · USNational Institutes of Health · USOregon Health & Science University · USPeking University · CNQueen's University Belfast · GBRetina Vitreous Associates Medical Group · USSan Raffaele University of Rome · ITSt. Franziskus Hospital · DETexas Retina Associates (United States) · USThe University of Melbourne · AUTokyo Medical and Dental University · JP

Funding

Department of Health 07/36/01Department of Health 12/142/07Intramural NIH HHS Z99 EY999999
6 · The paper itself

Abstract

purposeTo establish a process to evaluate and standardize a state-of-the-art nomenclature for reporting neovascular age-related macular degeneration (AMD) data.

designConsensus meeting.

participantsAn international panel of retina specialists, imaging and image reading center experts, and ocular pathologists.

methodsDuring several meetings organized under the auspices of the Macula Society, an international study group discussed and codified a set nomenclature framework for classifying the subtypes of neovascular AMD and associated lesion components.

main outcome measuresA consensus classification of neovascular AMD.

resultsThe study group created a standardized working definition of AMD. The components of neovascular AMD were defined and subclassified. Disease consequences of macular neovascularization were delineated.

conclusionsThe framework of a consensus nomenclature system, a definition of AMD, and a delineation of the subtypes of neovascular AMD were developed. Establishing a uniform set of definitions will facilitate comparison of diverse patient groups and different studies. The framework presented is modified and updated readily, processes that are anticipated to occur on a periodic basis. The study group suggests that the consensus standards outlined in this article be used in future reported studies of neovascular AMD and clinical practice.

Indexed as

Terminology as TopicAgedBruch MembraneChoroidal NeovascularizationConsensusFemaleHumansMaleRetinal Pigment EpitheliumVisual AcuityWet Macular Degeneration

Identifiers

PMID31864668
PMCPMC11559632
OpenAlexW2988969159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.